The Smoke Shop Sample Was Free. The Withdrawal Wasn't.

Nathan B. was a college football player when a clerk at a smoke shop near campus handed him a free sample. Not a pitch, not a sale — a sample, the way a grocery store hands out cheese cubes. It was a 7-hydroxymitragynine shot, sold as a legal, over-the-counter pick-me-up next to the energy drinks and rolling papers. He didn’t know the name for what was in it. Within months he did: he knew it as the thing he needed to feel normal, then the thing he needed to not feel sick, then the thing that cost him his girlfriend, his job, his house, his cars, his pets, and years of sobriety he’d already fought for once. He is now in Medicaid-covered treatment at Packard Health in Michigan, rebuilding from a substance that, when he first tried it, wasn’t illegal anywhere in the country.

The DEA tried to ban this drug into nonexistence, and it succeeded mainly at moving the crisis from the smoke shop to the detox ward.

That’s the shape of what clinicians are now describing, and the numbers are not subtle. At Boulder Care, a telehealth addiction clinic, the share of new patients reporting kratom use climbed from 3% in September 2025 to 8% by July 2026 to 14% in August — a near-fivefold jump in eleven months. At two Recovery Centers of America inpatient sites in Massachusetts, kratom-related admissions went from fewer than one patient a week to 10 to 20 a week. Nationally, lifetime kratom use rose from roughly 4 million people in 2019 to about 5 million in 2023, and poison-control reports involving kratom climbed from 258 to 3,434 over the past decade, according to data reported by STAT News.

What kratom actually is, and why 7-OH changes the math

Kratom is a tropical tree in the coffee family, native to Southeast Asia, where its leaves have been chewed or brewed as a mild stimulant and pain reliever for generations. At low doses it acts something like a stimulant; at higher doses, some of its compounds bind to the same opioid receptors that heroin and oxycodone do — just weaker. That’s the plant. What’s driving this surge is not the plant. It’s a refinement of one molecule inside it: 7-hydroxymitragynine, or 7-OH, a minor, weak component in raw kratom leaf that manufacturers have learned to concentrate and synthesize into shots, tablets, and gummies sold as intensified, fast-acting products — sometimes at potency multiples of what a leaf could ever deliver naturally. The plain-language version: think of the difference between chewing a coca leaf and using refined cocaine. Same botanical ancestor, entirely different drug in your body.

That distinction is exactly what federal regulators are now trying to legislate around, and exactly what’s proving hard to do cleanly.

”We’re basically treating it as if it’s fentanyl”

Ayesha Appa, head of medical affairs at Boulder Care, put the trend in blunt terms: “That really is quite an explosion,” she told STAT, describing the jump in new patients reporting kratom use. Her working theory is one any harm reduction worker would recognize on sight — restrict the legal supply, and the people already dependent on it don’t disappear, they show up somewhere else, sicker: “I think we’re really seeing and feeling what happens when people lose access and need to seek care in unprecedented numbers.”

At Recovery Centers of America in Massachusetts, medical director Myles Jen Kin described a clinical posture shift that would have sounded strange two years ago. “We’re basically treating it as if it’s fentanyl or oxycodone or heroin,” he said — meaning his teams now run buprenorphine induction protocols, the same medication-assisted treatment backbone used for opioid use disorder, on patients whose drug of use was, until recently, sold legally at a gas station. Phil Smyth, executive director of Milestone Treatment Center, described the pattern he sees at intake: “The common story I get from a lot of these clients is that they didn’t know” how dependent they’d become, or how strong the product actually was, until they tried to stop.

At Recovery Centers of America in Massachusetts, medical director Myles Jen Kin described a clinical posture shift that would have sounded strange two years ago.

If you’ve ever been handed something “natural” or “legal” and assumed that meant safe, you already understand the trap here. Legality was never a proxy for how a drug behaves in your bloodstream — it’s a proxy for what a legislature has gotten around to regulating, and legislatures move slower than product chemistry.

The ban that hasn’t finished happening yet

Here is the part that makes this more than a trend story, and the part we’ve been tracking since the ban’s blast radius first became clear: the federal action driving some of this access shock is not even finished being written. On July 1, 2026, the DEA filed notices with the Federal Register proposing to temporarily place concentrated 7-OH — above a specified threshold — into Schedule I for two years, alongside three related synthetic derivatives (mitragynine pseudoindoxyl, MGM-15, and MGM-16). HHS and FDA publicly backed the move, framing concentrated 7-OH as an emerging opioid threat. Crucially, the notices explicitly exclude raw, naturally occurring kratom leaf — the plant itself stays legal; it’s the refined, high-potency products the rule targets, according to the Spencer Fane legal analysis of the filing.

The three synthetic derivatives went Schedule I on August 25, 2026. The core rule — the one covering concentrated 7-OH itself, the ingredient actually driving the products people like Nathan B. were using — had its public comment period extended, to September 10, 2026, and a final Attorney General decision is still pending as of this writing. States, meanwhile, haven’t waited: numerous states have already enacted their own 7-OH restrictions ahead of any federal action, which is a meaningful part of why Appa’s patients are showing up now rather than in October.

We have watched this exact mechanism play out before, and the pattern has a name. In 1985, facing growing recreational use of MDMA, the DEA used its emergency scheduling authority to place it in Schedule I over the objection of its own administrative law judge, who had recommended Schedule III specifically to preserve research and clinical access. Congress followed a year later with the Federal Analogue Act of 1986, a law written to automatically criminalize any new chemical “substantially similar” to a banned one — an attempt to schedule an entire family of future molecules before chemists could invent them. What it produced instead was forty years of underground chemistry racing regulation, each new analogue arriving with less safety data than the one before it, because the whole point of an analogue is that nobody’s studied it yet. Concentrated 7-OH is that same move, run again, on a different molecule, by regulators who watched the last forty years and are still choosing the ban-first playbook.

What actually happens in your body when this drug leaves

Here’s the part clinics are relearning in real time, and it’s worth explaining plainly, because the fear of it is often what keeps people using rather than what gets them help. When a drug has spent months binding opioid receptors — even weakly, even from something sold as a supplement — your nervous system adapts to its presence. Stop suddenly, and the adaptation doesn’t reverse instantly; it reverses through withdrawal: nausea, sweating, muscle aches, insomnia, anxiety, and craving that isn’t a character flaw but a measurable physiological state. Researchers increasingly describe craving not as a symptom that follows dependence but as an active input into decision-making itself — a 2026 study in Nature Mental Health found that moment-to-moment craving intensity directly altered how people’s brains weighed rewards and made choices in real time, not after the fact. That’s the science behind something every person who’s been through withdrawal already knows in their body: it is not just discomfort, it is a state that reorganizes what your brain treats as urgent. Katherine Hill, an epidemiology researcher at Yale studying kratom, is among those now working to quantify exactly how that withdrawal profile compares to classic opioids — early clinical consensus, per the clinicians above, is that it’s close enough to warrant the same medications.

When a drug has spent months binding opioid receptors — even weakly, even from something sold as a supplement — your nervous system adapts to its presence.

What this means for a provider’s next intake

If you’re a case manager or clinician reading this before your next shift — the kind of treatment-recovery work this newsroom tracks daily across every novel and emerging substance class we cover — ask about kratom and 7-OH by name during intake, not as an afterthought after the standard opioid panel — many patients, per Smyth’s account, don’t identify what they were using as an opioid at all, so a generic “opioid use” screening question can miss it entirely. If a patient reports smoke-shop or gas-station “kratom shots,” “OPMS,” or branded 7-OH products, treat the withdrawal risk assessment the way you would for any full-agonist opioid, not a supplement. And if you’re building a team meeting agenda this week, this is worth ten minutes: ask whether your intake forms even have a checkbox for it.

None of this changes what’s still true and still working: buprenorphine protocols are helping the patients described in this story get stable, Medicaid coverage got Nathan B. into treatment at Packard Health, and naloxone remains just as effective if a 7-OH product is involved in an overdose as it is for any other opioid — that safety net hasn’t moved, whatever else has.

Nathan B. is rebuilding now, in a clinic, on a program, with a name for what happened to him. He didn’t get a warning label the day the clerk handed him that sample. The next person standing at that same counter still won’t — the rule that would have stopped the sale is still sitting in a comment period, waiting on an Attorney General’s signature, while the clinics count how many people walked in this week already withdrawing.